

DESCRIPTION

| | |
|---------------------------|--|
| Species Reactivity | Human |
| Specificity | Detects human ALK-1 in Western blots. In Western blots, approximately 1% cross-reactivity with recombinant human (rh) Activin R1A and rhActivin R1B is observed. |
| Source | Polyclonal Goat IgG |
| Purification | Antigen Affinity-purified |
| Immunogen | Mouse myeloma cell line NS0-derived recombinant human ALK-1 Asp22-Gln118 Accession # P37023 |
| Formulation | Lyophilized from a 0.2 µm filtered solution in PBS with BSA as a carrier protein. See Certificate of Analysis for details. |

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

| | Recommended Concentration | Sample |
|---------------------|---------------------------|---|
| Western Blot | 0.1 µg/mL | Recombinant Human ALK-1 Fc Chimera (Catalog # 370-AL) |

PREPARATION AND STORAGE

| | |
|--------------------------------|---|
| Reconstitution | Reconstitute at 0.2 mg/mL in sterile PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | <p>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</p> <ul style="list-style-type: none"> ● 12 months from date of receipt, -20 to -70 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 6 months, -20 to -70 °C under sterile conditions after reconstitution. |

BACKGROUND

Transforming Growth Factor beta (TGF-β) superfamily ligands exert their biological activities via binding to heteromeric receptor complexes of two types (I and II) of serine/threonine kinases. Type II receptors are constitutively active kinases that phosphorylate type I receptors upon ligand binding. In turn, activated type I kinases phosphorylate downstream signaling molecules including the various smads. Transmembrane proteoglycans, including the type III receptor (betaglycan) and endoglin, can bind and present some of the TGF-β superfamily ligands to type I and II receptor complexes and enhance their cellular responses. Seven type I receptors (also termed activin receptor-like kinase (ALK)) and five type II receptors have been isolated from mammals. ALK-2, -3, -4, -5, and -6 are also known as Activin R1A, BMPR-1A, Activin R1B, TGF-β R1, and BMPR-1B, respectively, reflecting their ligand preferences. Evidence suggests that TGF-β1, TGF-β3 and an unknown ligand present in serum can activate chimeric ALK-1. ALK-1 shares with other type I receptors a cysteine-rich domain with conserved cysteine spacing in the extracellular region, and a glycine- and serine-rich domain (the GS domain) preceding the kinase domain. ALK-1 is expressed highly in endothelial cells and other highly vascularized tissues. The expression patterns of ALK-1 parallels that of endoglin. Mutations in ALK-1 as well as in endoglin are associated with hereditary hemorrhagic telangiectasia (HHT), suggesting a critical role for ALK-1 in the control of blood vessel development or repair. Human and mouse ALK-1 share approximately 71% amino acid sequence identity in their extracellular regions.

References:

1. ten Dijke, P. *et al.* (1993) *Oncogene* **8**:2879.
2. ten Dijke, P. *et al.* (1994) *Science* **264**:101.
3. Lux, A. *et al.* (1999) *J. Biol. Chem.* **274**:9984.